Vivani Medical is a preclinical stage biopharmaceutical company which develops miniaturized, subdermal implants utilizing its proprietary NanoPortal™ technology to enable delivery of a range of medicines to treat chronic diseases. Co.'s pipeline programs are: NPM-119, which is in preclinical stage development for the treatment of patients with type 2 diabetes; OKV-119, which is under development for the treatment of obese and diabetic companion cats; NPM-139, which is in feasibility testing for the treatment of patients with obesity; and NPM-159, which is in feasibility testing for the treatment of patients with non-alcoholic steatohepatitis. The VANI average annual return since 2014 is shown above.
The Average Annual Return on the VANI average annual return since 2014 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether VANI average annual return since 2014 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the VANI average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|
Free VANI Email Alerts:
Video: Don't Forget Dividends in Average Annual Return!
